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Abstract
Antigen receptor signaling in lymphocytes has been clearly
implicated in the pathogenesis of the rheumatic diseases. Here, we
review evidence from mouse models in which B-cell and T-cell
signaling machinery is perturbed as well as data from functional
studies of primary human lymphocytes and recent advances in
human genetics. B-cell receptor hyper-responsiveness is identified
as a nearly universal characteristic of systemic lupus erythema-
tosus in mice and humans. Impaired and enhanced T-cell receptor
signaling are both associated with distinct inflammatory diseases in
mice. Mechanisms by which these pathways contribute to disease
in mouse models and patients are under active investigation.
Introduction
The classic concept of autoimmune disease rests upon the
notion that the adaptive immune system generates inappro-
priate antigen-specific responses to self epitopes which in
turn drive disease. Indeed, the presence of autoantibodies is
one of the most characteristic features of the rheumatic
diseases. Since the canonical definition of the adaptive
immune response relates to the ability of somatic recombi-
nation to produce an enormous range of antigen receptors on
lymphocytes, it follows that antigen receptor signal trans-
duction ought to play a role in autoimmune diseases. The T-
cell antigen receptor (TCR)-beta chain was cloned in 1983,
and the subsequent decade saw the discovery of the signal
transduction pathway downstream of the TCR [1]. Parallel
discoveries for B-cell antigen receptor (BCR) signaling
followed. Not only antigen receptors themselves but the
complex machinery that elaborates the cellular response to
antigen have been implicated in the rheumatic diseases. The
past decade has seen evidence confirm this view from a
range of sources, including engineered and spontaneous
mouse models, primary lymphocytes from patients, as well as
human genetics. Here, we provide a selective overview of
some of these advances and propose some general princi-
ples that tie these observations together.
Overview of antigen receptor signal transduction
TCR signal transduction is initiated following interaction of
the TCR αβ chains with peptide antigen bound to major
histocompatibility complex (MHC) class I or II molecules. The
signal is transmitted to a complex network of kinases,
phosphatases, and adaptors (Figure 1). The TCR αβ chains
lack any ability to transmit signals on their own and depend
on CD3 (ε, δ, and γ) and ζ chains that contain varying
numbers of immunoreceptor tyrosine-based activating motifs
(ITAMs). The dual tyrosines of ITAMs are phosphorylated by
the Src family kinases (SFKs), which, in T cells, are Lck and
Fyn. Dually phosphorylated ITAMs, in turn, form docking sites
for the tandem SH2 domains of Syk family kinases, ZAP-70
and Syk. The Syk kinases are activated upon binding to
phospho-ITAMs and phosphorylation by the SFKs. Once
activated, the Syk kinases phosphorylate the critical adaptors
Slp-76 and Lat, which together form the scaffolds for
assembly of further signaling molecules. Among these is the
enzyme phospholipase C γ1 (PLCγ1), which is responsible
for transmission of signals to phosphorylate mitogen-
activated protein kinases (MAPKs) and increase cytoplasmic
free calcium. Functional consequences of antigen receptor
signaling are varied and context-dependent, including cell
activation, proliferation, differentiation, and death [2,3].
In addition to antigen binding, there are many levels of
regulation in this signaling pathway. The SFKs themselves are
tightly regulated by phosphorylation of their inhibitory C-
terminal tyrosine residue. Reciprocal regulation of this phos-
photyrosine by the receptor-like tyrosine phosphatase CD45
and the cytoplasmic kinase Csk can set thresholds for
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antigen receptor signal transduction. Added complexity is
presented by tight regulation of the activating tyrosine of the
SFKs. Negative regulators of TCR signaling, such as the
phosphatases Pep and SHP-1, can dephosphorylate this
critical residue [4,5].
The BCR immunoglobulin chains are responsible for antigen
recognition (Figure 2). BCR signal transduction resembles
TCR signaling in many ways, relying upon the ITAMs of the
associated Igα and Igβ chains, the B-cell-expressed SFKs
Lyn, Fyn, and Blk, and the Syk kinase as well as homologous
adaptors (Blnk/Slp-65 instead of Slp-76). CD45 and Csk
also regulate SFKs in B cells as they do in T cells [6].
Multiple pathways feed into this network at several proximal
signaling nodes, including positive and negative regulators of
antigen receptor signaling. In T cells, for instance, the
coreceptors CD4 and CD8 play a positive regulatory role not
only by facilitating MHC recognition, but also by bringing the
SFK Lck into the proximity of the TCR [2]. The complex of
CD19/CD81/CD21 (CR2, complement receptor-2) that
interacts with the Lyn SFK plays a similar coreceptor role on
B cells. These coreceptors are counterbalanced by the action
of receptors with negative regulatory function. Cell surface
molecules that exert negative regulation often contain a
cytoplasmic motif, called an ITIM (immune tyrosine inhibitory
motif), which upon phosphorylation by SFKs recruits negative
regulators of signaling, such as the protein tyrosine
phosphatases SHP-1 and SHP-2 and the lipid phosphatase
SHIP. Such ITIM-containing receptors are best characterized
in B cells and natural killer cells. Inhibitory phosphatases,
once localized to the plasma membrane by phosphorylated
ITIMs, are placed in proximity to ITAM-containing receptors
and, in turn, negatively regulate their function. CD22 and
FcγRIIb are examples of B-cell-specific ITIM-containing
surface receptors that are critical modulators of BCR
signaling [7,8]. Inhibitory cell surface molecules such as PD-1
and CTLA-4 are expressed on T cells and analogously
modulate TCR signal transduction, although only PD-1
contains a canonical ITIM [9]. Despite abundant similarities,
wiring differs critically between T and B cells and among
distinct stages of lymphocyte development. Most notably, the
Lyn SFK in B cells is felt to play a non-redundant negative
regulatory role downstream of numerous ITIM-containing
receptors [10]. A homologous ‘negative’ role for Lck or Fyn in
T cells has yet to be clearly demonstrated.
Antigen receptor signaling in lymphocyte
development
Studies in mice have revealed that antigen receptor signaling
is critical not only in the response of mature lymphocytes to
foreign antigen but in the progression of lymphocytes through
a series of developmental stages in which both ligand-
dependent and ligand-independent signals are required to
proceed. Perhaps most significantly, antigen receptor signal-
ing is necessary for ‘testing’ and refining the antigen receptor
repertoire during development. Candidate TCRs are tested in
the thymus for ‘just right’ signal strength by positive and
negative selection. Perturbations in TCR signal transduction
influence this process [11]. Analogous processes have been
Figure 1
Schematic representation of T-cell receptor signal transduction.
CD4-associated Lck is reciprocally regulated by CD45 and
Csk/PTPN22 and in turn phosphorylates CD3 chain immunoreceptor
tyrosine-based activating motifs (ITAMs) and ZAP-70. ZAP-70
phosphorylates additional downstream effectors, including the
adaptors Slp-76 and Lat. Yellow bands represent CD3 chain ITAM
domains. Phosphotyrosines are not depicted on all CD3 chain ITAMs.
MAPK, mitogen-activated protein kinase; PLCγ1, phospholipase C γ1;
TCR, T-cell antigen receptor.
Figure 2
Schematic representation of B-cell receptor signal transduction. Lyn is
reciprocally regulated by CD45 and Csk and in turn phosphorylates
B-cell antigen receptor (BCR) immunoreceptor tyrosine-based
activating motifs (ITAMs) as well as immune tyrosine inhibitory motif
(ITIM)-containing immunoreceptors. Positive and negative signals are
in turn transmitted by Syk and SHP-1, respectively. Yellow bands on
Igα and β chains represent ITAM domains. Orange bands on CD22
and FcγRIIb represent ITIM domains. MAPK, mitogen-activated protein
kinase; PLCγ2, phospholipase C γ2.
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identified in B cells in the bone marrow and the periphery
[12]. Thymic lineage decisions have been shown to critically
depend upon antigen receptor signal strength, including
Foxp3+ regulatory T cell (Treg) fate [13]. Antigen receptor
signaling in the periphery is also critical in the maintenance of
immune homeostasis and tolerance to self. These antigen
receptor-dependent events are likely relevant for the
interpretation of disease pathogenesis in signaling mutants.
Mouse models
An extensive mouse model literature can teach us about the
signaling requirements for tolerance and autoimmunity.
Evidence for the role of antigen receptor signaling in auto-
immunity and insight into disease pathogenesis comes from
both forward and reverse genetic approaches, involving both
engineered and spontaneous mutations. Our approach here
is to group mutations with similar functional consequences
(hypo- or hyper-responsiveness) in T cells or B cells and to
explore links to disease.
B-cell antigen receptor signaling mutants and murine
lupus
Several single-gene mutants develop a lupus-like disease
characterized by the production of anti-nuclear antibodies
(ANAs) in the context of hyper-responsive BCR signaling.
Examples include FcγRIIb–/–, Lyn–/–, Lynup/up, CD45 E613R,
CD22–/–, CD19 transgenic (Tg), and SHP-1 (Mev) mice (see
[14] for detailed review). These mutations, in turn, can be
grouped into functional pathways. CD22, FcγRIIb, and SHP-1
are exclusively negative regulators of BCR signaling [6]. The
moth-eaten viable allele of SHP-1 (Mev) is a spontaneously
arising hypomorph with reduced phosphatase activity [14].
The SFK Lyn plays a more complex role in BCR signal
transduction [10]. A confusing observation has been that two
opposing alleles of Lyn (Lyn–/– and Lynup/up) both produce B-
cell hyper-responsiveness and ANAs. This strongly suggests
that Lyn has both positive and negative regulatory roles. Lyn
is critical for BCR signal transduction as well as function of
inhibitory coreceptors such as FcγRIIb and CD22. Lyn exerts
its negative regulatory role by phosphorylating ITIMs that in
turn recruit SHP-1 and SHIP. Lyn is thought to subserve this
function in a non-redundant fashion despite expression of two
other SFKs in B cells, Fyn and Blk. CD19 is a B-cell-specific
cell surface protein that forms the signaling component of the
CR2 complement receptor (CD21) in conjunction with CD81
[6]. CD19 contains multiple tyrosines and positively regulates
BCR signal transduction. Its overexpression in mice leads to
the production of autoantibodies [15]. E613R is a
dysregulated allele of CD45, which in turn influences SFK
activity. Mice harboring this mutation develop a lympho-
proliferative syndrome and a lupus-like disease on permissive
genetic backgrounds [16]. The disease is driven by B cells
that are extremely hyper-responsive to BCR signaling [17].
The characteristics of the disease(s) in these animals are
interesting. All produce autoantibodies but their specificities
vary. CD22–/– mice produce anti-cardiolipin antibodies and
anti-myeloperoxidase antibodies, whereas CD19 Tg mice
produce single-stranded DNA antibodies as well as
rheumatoid factor [15,18]. This observation suggests that
there may be a common general mechanism for autoantibody
production in various autoimmune diseases. It has recently
been demonstrated that the innate pattern recognition recep-
tors TLR7 and TLR9 are critical (and sufficient in a B-cell-
intrinsic manner) to generate antibodies to DNA/nuclear
components broadly and to direct specificities as well [19]. It
is likely that BCR signal transduction cooperates with this
pathway. Whether other factors cooperate and which ones
do so are still unknown. This exciting discovery complicates
conventional distinctions between innate and adaptive
responses and undercuts assumptions about clonal escape
from tolerizing mechanisms.
A general feature of this collection of mouse models is that
genetic background effects are very significant. FcγRIIb
develops lupus-like disease on the B6 background but not on
the Balb/c background [20]. CD45 E613R mice, in contrast,
remain healthy with no ANAs on the B6 background, whereas
on the Balb/c background 100% of the animals develop
ANAs (M Hermiston, V Lam, R Mills, N Oksenberg, N Cresalia,
A Tam, M Anderson and A Weiss, manuscript in preparation).
Furthermore, a number of these models can produce disease
on a ‘non-autoimmune’ background in the setting of
cooperating mutations [20].
When and how is tolerance broken in these mice? The
answer to this question is exceedingly complex because
many of these models influence cell lineages other than B
cells. Indeed, genetic deletion of lymphocytes in Mev mice
does not fully rescue disease, suggesting that myeloid cell-
intrinsic defects can drive the motheaten phenotype [21].
To understand how and where enhanced BCR signal trans-
duction produces autoantibodies, we will focus our attention
on those mice in which signaling is perturbed only in B cells.
We are left with the CD22–/–, FcγRIIb–/–, and CD19 Tg
models. FcγRIIb–/– is the most extensively studied of these,
and crosses to BCR transgenes have revealed that the
tolerance break is peripheral and ‘late’ [22]. Similarly, CD22
is expressed and influences signaling in a relatively narrow
pattern upon mature conventional B cells [14]. Lyn–/– (Andrew
Gross, personal communication) and CD45 E613R (J
Zikherman, M Hermiston, D Steiner, K Hasegawa, A Chan, A
Weiss, manuscript in preparation) B cells also exhibit hyper-
responsiveness to BCR stimulation predominantly at the
follicular mature peripheral B cell stage of development.
Taken together, these data suggest that peripheral BCR
hyper-responsiveness cooperates with other events (such as
TLR signaling) to break tolerance by accelerating
differentiation into plasma cells or progression into germinal
centers. It may be that sufficient ‘escape’ of anti-nuclear B
cells to the periphery occurs physiologically [23]. A ‘central’
Available online http://arthritis-research.com/content/11/1/202
tolerance break may not be necessary in these mouse models
of lupus.
In other mouse models, both a central and peripheral
tolerance break may be required. The NZB/W mouse is a
spontaneous polygenic model of lupus which has been
studied extensively over the last 20 years. Genetically separ-
able cellular phenotypes resemble those seen in engineered
models of lupus. For example, BCR hyper-responsiveness
maps to the lupus-prone NZM2410-derived Sle2 genetic
locus but cannot independently produce disease [24]. The
Sle1 region is associated with the appearance of ANAs [25].
Sle1 recently was mapped to Ly108, a member of the SLAM
family of receptors that signal through a non-ITAM/ITIM
pathway that relies upon the adaptor SAP and the SFK Fyn
[26]. Ly108 is highly expressed in immature B cells and can
modulate BCR signal strength. The NZB/W-derived allele of
Ly108 produces weaker BCR signaling than the B6 allele in
immature B cells. This allele may act early during negative
selection of B cells, permitting polyreactive anti-double-
stranded DNA (anti-dsDNA) B cells to escape to the periphery.
Thus, opposing signaling phenotypes may be required to
breach ‘central’ and ‘peripheral’ tolerance mechanisms. The
two may even coexist in the same animal as genetically
separable phenotypes as demonstrated by the NZB/W lupus
model. Whether analogous functional phenotypes charac-
terize human systemic lupus erythematosus (SLE) will be
interesting to determine.
Proximal T-cell antigen receptor signal transduction
and autoimmune disease
There are many examples of signaling mutants in which
proximal TCR signaling machinery is impaired, and a number
of these mutants develop disease. The Skg mouse model of
rheumatoid arthritis (RA) is due to a spontaneous mutation
that arose in an inbred colony of Balb/c mice [27]. These
animals develop a destructive polyarthritis associated with
rheumatoid factor and anti-cyclic citrullinated peptide
antibody production. The mutation was identified as a single
amino acid substitution in ZAP-70 (W613C). This mutation
impairs ZAP-70 association with TCRζ-chain ITAMs and
results in markedly reduced TCR signal transduction. The
mice exhibit impaired positive and negative selection in the
thymus as well as a hypo-proliferative phenotype in the
periphery. Consistent with a ZAP-70 mutation, the disease is
T-cell-mediated; CD4 T cells, but not serum, can transfer the
disease, even into RAG–/– hosts lacking endogenous T and B
cells [28]. 
The pathogenesis of disease in these animals remains
unclear [28]. Impaired negative selection has been observed
and may permit autoreactive T cells to escape to the
periphery. However, a bona fide autoantigen has not yet been
identified. Other potential etiologies of disease include
abnormalities in Tregs, which are reduced in number and
impaired in function. Whether Tregs play a critical role in the
pathogenesis of Skg arthritis is still uncertain. Cytokine milieu
appears to be perturbed in these animals, and dysregulated
T-cell differentiation and cytokine production may play an
important role. Indeed, crosses to cytokine knockouts have
shown that IL-6 and IL-17, but not interferon-gamma, are
required to mediate disease. Interestingly, the disease
disappeared in a clean specific-pathogen-free facility but
could be induced by innate immune stimulation of pattern
recognition receptors by dectin, a fungal cell wall component
[29]. Thus, the dysregulated immune system in these animals
has to be tipped over the edge, so to speak.
An informative allelic series of ZAP-70 hypomorphic mutants
was described recently and provided an opportunity to study
graded TCR signaling and its role in autoimmunity [30]. The
ZAP-70 allelic series revealed a threshold effect in which
partial, but neither mild nor severe, T-cell immunodeficiency
was sufficient to break tolerance. Partially impaired TCR
signal transduction was associated with the appearance of
ANAs as well as hyper-IgE and IgG1 antibody production.
The latter suggests an unusual Th2 polarization, which we will
mention again below in the context of other mutants.
This phenotype did not resemble the ZAP-70 hypomorphic
Skg allele. The ZAP-70 allelic series was generated on the B6
genetic background, whereas the Skg ZAP-70 allele leads to
arthritis only on the Balb/c background in the context of an
innate immune stimulus. A common target molecule with
quantitatively or qualitatively impaired TCR signaling may
provoke different diseases in different genetic and environ-
mental contexts, as seen with B-cell perturbations. The mouse
models discussed above include quantitative and perhaps
qualitative impairments in a single critical molecule, ZAP-70,
involved in TCR signal transduction. What of perturbations in
distinct signaling pathways downstream of the TCR?
The Lat Y136F mutation eliminates binding of PLCγ1 to a
critical phospho-tyrosine of the Lat adaptor [31,32]. T cells
from Lat Y136F mice exhibit profoundly impaired calcium flux
with relatively preserved Erk phosphorylation. Thymic develop-
ment is perturbed with a partial block at beta selection as well
as positive selection. At 2 to 3 weeks of age, the mice
develop a lymphoproliferative disorder characterized by CD4
T-cell expansion and overproduction of Th2 cytokines. The
mice exhibit associated polyclonal B-cell activation and
elevation of IgE and IgG1. An inflammatory disease develops
with multiorgan infiltrates and production of ANAs as well as
dsDNA antibodies. The phenotype is much more severe than
that associated with the ZAP-70 allelic series, but the unusual
development of Th2 cytokine overproduction (and hyper-IgE
levels) is reminiscent.
Taken together, the pathogenesis of autoimmunity in these
models is not obvious [33]. Clearly, impaired signal trans-
duction perturbs thymic selection and influences the T-cell
Arthritis Research & Therapy    Vol 11 No 1 Zikherman and Weiss
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repertoire. However, as in the Skg mouse, initiating auto-
antigens have not been identified and how an autoantigen
could stimulate severely signaling-impaired peripheral T cells
to produce disease is unclear. Lineage commitment in the
thymus is also perturbed; Treg development and function are
abnormal. Indeed, a number of mouse models with impaired
TCR signaling and autoimmunity are rescued by transfer of
wild-type Tregs [33]. However, the ability of transferred Tregs
to reverse a disease phenotype does not establish Treg
deficiency as a cause of disease.
Another possibility raised in the context of these immuno-
deficiency states is that a lymphopenic environment may be
critical for homeostatic proliferation/activation of dysregulated
T cells. Also, partial immunodeficiency may perturb host
defense in such a fashion that the homeostatic burden of gut
commensals is abnormal. Stimulation of the innate immune
system may interact with abnormal T cells to wreak havoc.
A final hypothesis relates to abnormal homeostasis of
peripheral T cells. Impaired TCR signal transduction may alter
effector T-cell differentiation and function in multiple ways. It
may be that inhibitory feedback loops downstream of TCR
triggering are disproportionately impaired in these models
such that a weak signal is transmitted but not appropriately
downregulated. Alternatively, an appropriate signal to induce
anergy is not generated. This group of defects encompasses
failure of antigen-specific anergy as well as failure of non-
antigen-specific ‘self-control’.
Most recently, extensive characterization of the Lat Y136F
mouse model has produced unexpected results. The transfer
of Lat Y136F CD4 T cells into an MHC II–/– host produces
disease [34]. This raises the possibility that participation of
Lat in non-TCR signals (in a lymphopenic environment) or
ligand-independent tonic TCR signals (in the absence of
functional antigen-presenting cells) plays a role. Significantly,
proliferating Th2 polarized effector CD4 T cells drive ANA
production in wild-type B cells upon adoptive transfer in the
absence of a bona fide initiating autoantigen and certainly
cannot do so in a cognate manner (in the absence of MHC II
molecules).
Most rheumatologists would classify ANA production as
‘autoimmune’ in nature. It may, however, be important to
reassess old assumptions about the antigen-driven etiology
of ‘autoimmunity’ in animal models characterized by ANAs.
We have learned in recent years that innate receptors such
as the TLRs are required to direct this specificity and now
discover that non-specific T-cell help is sufficient to produce
ANAs in otherwise normal B cells.
Diseases that develop in the Lat model and in the ZAP-70
allelic series are characterized by IgE and Th2 cytokine over-
production. Autoimmunity that sometimes arises in the
context of partial human T-cell immunodeficiency is often
characterized by IgE production and ‘allergic’ Th2 diseases.
The ZAP-70 allelic series and Lat mouse models bear a much
closer resemblance to these relatively rare clinical entities
than to common polygenic rheumatic diseases such as RA
and SLE. (The reader is referred to an excellent recent review
[33].) Nevertheless, this phenomenon raises the possibility
that dysregulation of T-cell-intrinsic effector pathways may
contribute to disease in some ‘classic’ rheumatic diseases.
Hyper-responsive T-cell antigen receptor signaling
We have observed that B-cell hyper-responsiveness appears
to be an overwhelming characteristic of murine lupus mouse
models. A large number of mice with impaired TCR signaling,
with either proximal or distal transduction perturbations,
develop dysregulated lymphoid homeostasis and inflam-
matory diseases [33]. Only a handful of these have been
reviewed here, selected because they feature proximal and T-
cell-specific perturbations that are more easily interpretable
and simplify the cellular mechanisms of disease.
The clearest model to demonstrate that T-cell hyper-respon-
siveness can also break tolerance may be the Cbl/Cbl-b
double-deficient mice. Cbl and Cbl-b are widely expressed
E3 ubiquitin ligases that target their substrates for proteo-
somal degradation [35]. By targeting multiple components of
the antigen receptor signal transduction machinery for
degradation, Cbl and Cbl-b serve as negative regulators of
antigen receptor signaling. Both single and double knockouts
(dKOs) have been generated, revealing overlapping as well
as developmentally distinct roles in antigen receptor signaling
[35]. The T-cell-specific dKO develops a severe systemic
disease characterized by arteritis and dsDNA production [36].
T cells are hyper-proliferative and produce large quantities of
cytokines in response to TCR stimulation. Yet proximal TCR
signaling machinery is differentially affected, with enhanced
ZAP-70 phosphorylation but impaired PLCγ1 phosphorylation
leading to impaired inducible calcium increase. Most
interestingly, impaired ligand-induced TCR downmodulation
and prolonged Erk phosphorylation characterize dKO T cells.
The TCR signaling phenotype is not simply amplified but is
qualitatively and kinetically perturbed. Whether the associated
disease represents an antigen-specific breach of tolerance or
a dysregulated polyclonal response akin to the Lat Y136F
mice remains unclear.
In contrast to impaired TCR signaling, relatively few mouse
models with a ‘pure’ defect leading to hyper-responsive
T cells develop autoimmune disease. One explanation relates
to the wiring of TCR signaling machinery and another to the
etiology of rheumatic disease. One can a priori engineer
hyper-responsive TCR signaling by generating either a
hypermorphic allele of a positive regulator or a knockout/
hypomorph of a negative regulator. Although knockouts are
easier to generate, negative regulators appear in general to
display more functional redundancy than positive regulators
of TCR signaling (the opposite may be true in B cells).
Available online http://arthritis-research.com/content/11/1/202
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Perhaps these mutants, when generated, have too subtle a
phenotype (for example, Pep–/–, to be discussed later) to
produce disease on non-autoimmune genetic backgrounds.
Another argument relates to the developmental
consequences of strong TCR signaling. Examples of
dramatically enhanced TCR signaling, including the Lck
Y505F mutant and the Csk–/– mutant, exist [5]. Both have
such enhanced TCR signaling that T-cell development in the
thymus cannot occur normally due to suppression of RAG
expression. In fact, rather than autoimmunity, these types of
perturbations cause malignant transformation. In this way,
hyper-responsive peripheral T cells may just be hard to
generate with reverse genetics in mice. Alternatively, it may
be that only impaired TCR signaling can breach T-cell
tolerance without help. Indeed, as we will argue below, hyper-
responsive T cells may be a feature of specific autoimmune
diseases that require an additional and independent B-cell
phenotype. Hyper-responsive T cells, in other words, may not
be able to act alone. Perhaps this tells us that our immune
system is biased toward protecting us from the ravages of
overactive T cells but has fewer built-in defenses against
impaired TCR signaling. This might make teleogical sense
since the overwhelming evolutionary pressure on the immune
system has been infection, not autoimmunity, driving the
system to over-reaction, not under-reaction.
Translational data: signaling in B and T cells
from patients with rheumatic disease
Do these mouse models have relevance for human disease?
Indeed, perturbations in antigen receptor signal transduction
have been identified in lymphocytes from patients with rheu-
matic diseases.
B cells in human systemic lupus erythematosus
Stimulation of the BCR on peripheral blood B cells from SLE
patients has been reported to cause exaggerated calcium
increases, recapitulating functional cellular phenotypes seen
in mouse mutants with SLE (for example, Lyn–/–, FcγRIIb–/–,
and CD22–/–) [37]. Significantly, these functional alterations
did not correlate with disease activity or with treatment,
consistent with a primary pathogenic role. The mechanistic
and genetic basis of this phenotype in primary human B cells
remains uncertain. Expression of key BCR signaling
molecules in SLE B cells has been studied and reduced
levels of the negative regulators Lyn and SHIP have been
described, reminiscent of SLE mouse models [38]. The
convergence of human and mouse data strongly suggests
that exaggerated BCR signal transduction, at least in
peripheral B cells, may be a fundamental pathogenic feature
of human SLE.
T cells in human systemic lupus erythematosus
Analogous functional studies of T cells from SLE patients
have been undertaken. Exaggerated calcium increases in SLE
T cells upon TCR stimulation have been reported [39]. Oddly,
SLE T cells generally produce reduced quantities of IL-2 [40].
This has been interpreted as an ‘anergic’ phenotype and might
suggest that some of the observed signaling phenomena
reflect the influence of a characteristic inflammatory milieu
rather than a cell-intrinsic genetic program.
Interestingly, expression levels of TCRζ chain were found to
be reduced in SLE T cells [39]. The mechanism for this de-
ranged expression is apparently both transcriptional and post-
translational [40,41]. Increased expression of the alternative
ITAM-bearing receptor FcRγ has been observed in those
cells, and TCR stimulation results in enhanced FcRγ
phosphorylation. An alternative TCR complex composed of
FcRγ-Syk (replacing ζ-Zap70) has been proposed to account
for the altered functional signaling phenotype observed in
these cells. Similar ζ chain downregulation in RA T cells from
synovial fluid and in memory T cells has been reported [40].
T cells in human rheumatoid arthritis
Interestingly, distinct functional phenotypes have been
reported in peripheral blood T cells from patients with RA,
including impaired calcium responses and proliferation to
TCR stimulation [42]. This is a provocative observation
given the T-cell-signaling-impaired Skg mouse, which
develops an RA-like clinical phenotype on a susceptible
genetic background.
In the end, whether these changes observed in SLE and RA
reflect a cell-intrinsic and disease-specific abnormality in
T cells or a general change to activated/effector status is less
clear, and whether in turn this represents a cause or effect of
the inflammatory disease is unknown.
Human genetics
Functional studies conducted with primary human cells are
suggestive but remain correlative. To address cause and
effect, human genetics offers some clues. Indeed, numerous
human candidate gene association studies have implicated
antigen receptor signaling pathways in the pathogenesis of
rheumatic diseases. A hypomorphic allele of FcγRIIb
(Ile232Thr) has been associated with SLE in an Asian
population [20]. Studies in recent years have also identified
disease-associated polymorphisms in CTLA-4, a T-cell
inhibitory coreceptor, and mutations that influence splicing
and function of CD45 [43,44]. Human genetics has seen an
explosion in data with the advent of whole genome
association studies in the last two years. Unbiased identi-
fication of new genetic risk factors for human autoimmune
diseases has implicated antigen receptor signaling machinery
as well [45]. The B cell SFK Blk and the BCR signaling
adaptor BANK1 were identified in recent whole genome
scans for lupus [46,47]. A single missense polymorphism in
PTPN22, a negative regulator of the SFKs, is the second
strongest common polymorphism associated with RA outside
of the MHC [48,49]. Yet the functional consequences of
many of these polymorphisms remain unclear. The subtlety of
the risk alleles coupled with developmental and network
Arthritis Research & Therapy    Vol 11 No 1 Zikherman and Weiss
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complexity of antigen receptor signal transduction make
interpretation of phenotypes challenging. How then can
polygenic susceptibility loci be studied? How do we move
from genetics to pathogenesis?
PTPN22 R620W polymorphism
An elegant example is the PTPN22 R620W polymorphism,
which is associated with multiple autoimmune diseases,
including SLE, RA, and type I diabetes [50,51]. The PTPN22
gene product Lyp, the murine ortholog of which is Pep,
encodes a hematopoietic cytoplasmic phosphatase. Pep/Lyp
negatively regulates TCR signaling by dephosphorylating the
activating tyrosine of Lck [52,53]. One quarter to one half of
Pep is found associated with Csk, a potent negative regulator
of TCR signaling which dephosphorylates the inhibitory
tyrosine of Lck [54]. Pep cooperatively inhibits TCR signaling
by binding Csk and this association in turn is mediated by a
proline-rich sequence in the C-terminal region of Pep (PRS1)
[52,54].
The R620W polymorphism is located in the critical PRS1
domain of Pep, and impairs the interaction of Pep with Csk
[50,55]. The risk allele was therefore initially postulated to
represent a loss-of-function in which TCR signaling was less
effectively inhibited. However, overexpression of the Lyp risk
allele in Jurkat cells suggested the opposite (that is, that the
risk allele is a gain-of-function, impairing TCR signaling) [55].
A handful of studies of primary human cells from healthy
donors as well as patients harboring the risk allele have been
published [55-58]. Several appear to confirm the gain-of-
function hypothesis but not all are in agreement. In our
laboratory, we revisited the question of the functional
significance of the R620W risk allele. Functional studies of
the wild-type and R619W (murine homolog) Pep alleles in
the context of Csk unmasked Pep R619W as a hypomorphic
allele (J Zikherman, M Hermiston, D Steiner, K Hasegawa, A
Chan, A Weiss,manuscript in preparation).
The Pep–/– mouse confirms Pep as a negative regulator of
TCR signaling but no disease phenotype is discernible [59].
Indeed, the Pep null allele appears to require a cooperating
mutation to develop disease, just as the R620W poly-
morphism in humans does not act alone. By crossing the
Pep–/– mice onto a background in which hyper-responsive B
cells (characteristic of lupus-prone mice and humans) are
active, we have been able to generate a mouse model in
which a bona fide human genetic risk factor produces a
lupus-like disease. In Pep–/–/CD45 E613R double-mutant
animals, hyper-responsive Pep–/– T cells and hyper-respon-
sive CD45 E613R B cells cooperate to break tolerance (J
Zikherman, M Hermiston, D Steiner, K Hasegawa, A Chan, A
Weiss, manuscript in preparation). Definitive functional
conclusions about the R620W allele will depend on future
studies of a knock-in mouse. Even those will then have to be
pursued in the context of cooperating mutations in order to
recapitulate human disease pathogenesis.
Conclusion
Conventional antigen-driven autoimmune disease with patho-
genic clones is most clearly observed in the organ-specific
autoimmune endocrinopathies, including insulin-dependent
diabetes mellitus, autoimmune ovarian failure, and others.
Certainly, polyendocrinopathy syndromes, and possibly spor-
adic variants of these diseases, appear to be characterized
by failure of central tolerance [60]. However, more and more
questions have been raised regarding the ‘autoimmune’
nature of diseases arising in the setting of partial immuno-
deficiency. The common systemic rheumatic diseases,
particularly SLE and RA, are under scrutiny as well. Conven-
tional models of disease pathogenesis are being revised as
the complex interplay of innate and adaptive pathways is
being dissected and appreciated. Are alterations in antigen
receptor signaling pathways significant in disease patho-
genesis? Overwhelming data suggest that they are. Are
specific auto-antigens required to break tolerance and drive
disease? This is less clear. We have tried in this review to
demonstrate the power of combining genetic and functional
studies in mice and humans and to point out the limits of our
current understanding. Much remains to be understood in the
pathogenesis of rheumatic diseases, and new targets for
therapy will no doubt emerge. 
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